{"nctId":"NCT03989232","briefTitle":"A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","startDateStruct":{"date":"2019-06-19","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":961,"armGroups":[{"label":"Semaglutide 2.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide"]},{"label":"Semaglutide 1.0 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Semaglutide","Drug: Placebo (semaglutide)"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Placebo (semaglutide)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age equal to or above18 years at the time of signing informed consent\n* Diagnosed with T2D at least 180 days prior to the day of screening\n* HbA1c of 8-10% (64-86 mmol/mol) (both inclusive)\n* Stable daily dose(s) for 90 days prior to the day of screening of:\n* Any metformin formulations (equal to or above1500 mg or maximum tolerated or effective dose) alone or in combination with sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)\n\nExclusion Criteria:\n\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes\n* Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \\<30 mL/min/1.73 m\\^2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation as defined by KDIGO 2012 classification\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c","description":"Change from baseline (week 0) to week 40 in glycosylated haemoglobin (HbA1c) was evaluated.\n\nResults are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first; and 'In-trial' observation period which started at the date of randomisation and ended at the first of the following dates, both inclusive: end-of-treatment visit (week 40), death, participant withdrew informed consent, last contact for participant lost to follow-up.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.0"},{"groupId":"OG001","value":"-2.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"1.0"},{"groupId":"OG001","value":"-2.2","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline (week 0) to week 40 in body weight was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first; and 'In-trial' observation period which started at the date of randomisation and ended at the first of the following dates, both inclusive: end-of-treatment visit (week 40), death, participant withdrew informed consent, last contact for participant lost to follow-up.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"5.8"},{"groupId":"OG001","value":"-7.0","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"5.9"},{"groupId":"OG001","value":"-6.7","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline (week 0) to week 40 in FPG was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"2.8"},{"groupId":"OG001","value":"-3.4","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change from baseline (week 0) to week 40 in BMI was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"2.1"},{"groupId":"OG001","value":"-2.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change from baseline (week 0) to week 40 in waist circumference was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"6.1"},{"groupId":"OG001","value":"-5.9","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved HbA1c < 7.0%","description":"Percentage of participants who achieved HbA1c \\< 7.0% is presented. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first. Missing HbA1c assessment at week 40 was imputed using observed data from participants within same treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"67.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved HbA1c ≤ 6.5%","description":"Percentage of participants who achieved HbA1c ≤ 6.5% is presented. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first. Missing HbA1c assessment at week 40 was imputed using observed data from participants within same treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Weight Loss ≥5%","description":"Percentage of participants who achieved weight loss ≥5% is presented. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first. Missing body weight assessment at week 40 was imputed using observed data from participants within same treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Weight Loss ≥10%","description":"Percentage of participants who achieved weight loss ≥10% is presented. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first. Missing body weight assessment at week 40 was imputed using observed data from participants within same treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"28.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes","description":"Hypoglycaemic episodes defined as treatment-emergent if the onset of the episode occurs within the on-treatment observation period. Severe or BG-confirmed symptomatic hypoglycaemia is an episode that required assistance from another person for recovery and blood glucose-confirmed by a plasma glucose value \\<3.1 mmol/L (56 milligrams per deciliter (mg/dL)) with symptoms consistent with hypoglycaemia. Results are based on the 'on-treatment' observation period, which started at the date of first dose of trial product and ended at the first date of any of the following: the follow-up visit (week 47), the treatment discontinuation follow-up visit (end of treatment + 7 weeks), the date of last dose of trial product +49 days or the end-date for the 'in-trial' observation period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Rate","description":"Change from baseline (week 0) to week 40 in pulse rate is presented. Results are based on the 'on-treatment' observation period, which started at the date of first dose of trial product and ended at the endpoint-specific end-date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"10.0"},{"groupId":"OG001","value":"3.3","spread":"9.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":480},"commonTop":["Nausea","Diarrhoea","Vomiting","Decreased appetite","Dyspepsia"]}}}